Panitumumab|CAS 339177-26-3|DC Chemicals

Cas No.:	339177-26-3
pH value:	Corresponds to reference standard： PASS
Non-reduced CE-SDS:	98.1%
SEC-HPLC:	99.2%
Isoelectric Point:	Corresponds to reference standard
Bacterial Endotoxins Test:	＜1 EU/ml
Exogenous Residual DNA:	＜1 pg/mg
Residual protein A:	＜1 ng/mg
Biological Activity:	Compared with standard, the range ofbiological activity is 115%
Osmolality:	Corresponds to reference standard: PASS
Peptide mapping:	Corresponds to reference standard: PASS
N-terminal sequence:	Corresponds to reference standard:PASS

Description:	Panitumumab, formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans).
References:	[1]. Yu Jo Chua, et al. Panitumumab. Drugs Today (Barc). 2006 Nov;42(11):711-9.

Cat. No.	Product name	Field of application
A1061	Osemitamab Biosimilar(Anti-CLDN18.2 Reference Antibody)	Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study.
A1060	Muromonab Biosimilar（Anti-CD3 Reference Antibody）	Muromonab is a monoclonal antibody targeting the CD3 receptor. Muromonab can block all cytotoxic T cell function. Muromonab also as an immunosuppressant agent given to reduce acute solid organ transplant rejection.
A1059	Atoltivimab Biosimilar（Anti-EBOV Reference Antibody）	Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection.
A1058	Navivumab Biosimilar（Anti-HA Reference Antibody）	Navivumab (CT-P23) is an influenza A virus hemagglutinin HA monoclonal antibody. neutralizes H1, H2, H5, and H9 influenza A viruses by binding to the stem fusion domain in HA2.
A1057	Anti-IAV Reference Antibody Biosimilar
A1056	Odesivimab Biosimilar（Anti-Zaire Ebola virus Reference Antibody）	Odesivimab is a human monoclonal antibody, targeting Ebola virus glycoprotein with a KD value of 7.74 nM for recombinant histidine-tagged Makona strain Ebola virus glycoprotein ectodomain protein. Odesivimab can be used in research of Ebola virus infection.
A1055	Cosfroviximab Biosimilar（Anti-Zaire Ebola virus Reference Antibody）	Cosfroviximab (c13C6-FR1) is a mouse/human chimeric monoclonal antibody against Ebola virus glycoprotein (EBOV-GP).
A1054	Porgaviximab Biosimilar（Anti-Zaire Ebola virus Reference Antibody）	Porgaviximab is a monoclonal antibody that can be used Ebola infection research.
A1053	Larcaviximab Biosimilar（Anti-Zaire Ebola virus Reference Antibody）	Larcaviximab (c4G7-N) is an IgG1 kappa anti-Ebola virus glycoprotein chimeric monoclonal antibody.
A1052	Romlusevimab Biosimilar（Anti-Spike RBD Reference Antibody）	Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).